Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ELLIPTA DPI Clear all
Recruiting Phase 4 Interventional

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

NCT07133880
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

NCT02799784
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, TIO/OLO, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 2, 2026, 4:00 PM EDT
Completed No phase listed Observational Results available

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

NCT03543176
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, FLUT/SAL, CAT, mMRC, Ellipta, Diskus
Other · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

NCT02586506
View directory record Official record
Conditions
Asthma
Interventions
Placebo ELLIPTA inhaler, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

NCT03380429
View directory record Official record
Conditions
Asthma
Interventions
RELVAR/BREO, Salbutamol, Smart phone app, HCP Dashboard, Sensors
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Aventura, Florida • Miami, Florida • Flossmoor, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

NCT03012061
View directory record Official record
Conditions
Asthma
Interventions
Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

NCT03478657
View directory record Official record
Conditions
Asthma
Interventions
Placebo DPI, ELLIPTA DPI, Ease of use questionnaires
Drug · Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Little Rock, Arkansas • Huntington Beach, California • Napa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03034915
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
2,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 2, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

NCT03248128
View directory record Official record
Conditions
Asthma
Interventions
FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
49
States / cities
Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03227445
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03474081
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02786927
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA device, Placebo capsules for use in HANDIHALER device, Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
22
States / cities
Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

NCT02691325
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 2, 2026, 4:00 PM EDT
Completed Phase 4 Interventional Results available

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

NCT04606394
View directory record Official record
Conditions
COPD
Interventions
Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Ventolin 90Mcg/Actuation Inhalation Aerosol
Drug
Lead sponsor
Pulmonary Research Institute of Southeast Michigan
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 2, 2026, 4:00 PM EDT